Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses concerns about automatic substitution of biosimilars for reference products.
Transcript:
Do you have concerns about automatic substitution of biosimilars for reference products?
Yes, I do and I guess I don’t, to some degree. I do have [concerns with] automatic substitution, but it depends on who is doing the substitution and what is being substituted. If I place someone on a new medication and instead of getting the bio-originator product, I get a biosimilar as my first medication, right now I have no qualms about that. The patient is starting on a new medication, it is what it is, and we will see how they respond. However, if they are already on a bio-originator product and they are switched over, I have some concerns about switching a patient who is doing well. The third avenue where you could see switching, which I would be very opposed to, would be someone who is on medication—we’ll say etanercept—and the insurance company or the payer decides that adalimumab biosimilar is the medication of choice. Switching a patient from one drug, not only to a biosimilar, but to a biosimilar of another medication, has huge implications and is very concerning for me. As a rheumatologist, the problem with rheumatoid arthritis is that early on, we have joint damage, and if you lose control of the disease activity, in the long run you can see worse outcomes with increasing rates of disability, etc.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.